CINXE.COM
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
<!DOCTYPE html> <html lang="en"> <head><meta charset="utf-8" /><title> Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements </title><link href="../../../Content/Site.css" rel="stylesheet" /><link href="../../../Content/bootstrap-3.3.2-dist/css/bootstrap.min.css" rel="stylesheet" /><link href="../../../Content/bootstrap-3.3.2-dist/css/bootstrap.icon-large.min.css" rel="stylesheet" /><link href="//maxcdn.bootstrapcdn.com/font-awesome/4.3.0/css/font-awesome.min.css" rel="stylesheet" /><link href="../../../Content/Custom.css" rel="stylesheet" /><link href="../../../favicon.ico" rel="shortcut icon" type="image/x-icon" /> <script src="/Scripts/modernizr-2.5.3.js"></script> <meta name="viewport" content="width=device-width" /> <script type="text/javascript" src="https://www.jcnnewswire.com/jquery/jquery-latest.min.js"> </script> <script type="text/javascript" src="https://www.jcnnewswire.com/jquery/jquery.fancybox.pack.js?v=2.1.5"></script> <link rel="stylesheet" type="text/css" href="https://www.jcnnewswire.com/jquery/jquery.fancybox.css?v=2.1.5" media="screen"> <style> .lang li { display:inline; } .lang a { color:#fff; } </style> <script type="text/javascript"> (function(c,l,a,r,i,t,y){ c[a]=c[a]||function(){(c[a].q=c[a].q||[]).push(arguments)}; t=l.createElement(r);t.async=1;t.src="https://www.clarity.ms/tag/"+i; y=l.getElementsByTagName(r)[0];y.parentNode.insertBefore(t,y); })(window, document, "clarity", "script", "559ucihkaw"); </script> </head> <body> <form method="post" action="./Anticancer-Agent-TASFYGO-Tablets-35mg-(Tasurgratinib-Succinate)-Launches-in-Japan-for-Biliary-Tract-" onsubmit="javascript:return WebForm_OnSubmit();" id="ctl01"> <div class="aspNetHidden"> <input type="hidden" name="__EVENTTARGET" id="__EVENTTARGET" value="" /> <input type="hidden" name="__EVENTARGUMENT" id="__EVENTARGUMENT" value="" /> <input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="/wEPDwUKLTU1NzE2ODMwMmRkT5KUbC84gQLg3I8yjxo3X0y1MchQa0NYGjYUYxWjN/k=" /> </div> <script type="text/javascript"> //<![CDATA[ var theForm = document.forms['ctl01']; if (!theForm) { theForm = document.ctl01; } function __doPostBack(eventTarget, eventArgument) { if (!theForm.onsubmit || (theForm.onsubmit() != false)) { theForm.__EVENTTARGET.value = eventTarget; theForm.__EVENTARGUMENT.value = eventArgument; theForm.submit(); } } //]]> </script> <script src="/WebResource.axd?d=YcG_1mlPARhRW7O4sA9bWHA-qI2d_t_BO06OeFBhoaiREhheyXs3-1psdTUSDOHCoQeBPKlq2r8vu_cSQNfig-Is-AxTXJhRKwfH8V2oM9c1&t=638611161180000000" type="text/javascript"></script> <script src="/WebResource.axd?d=bIpPyEdzAMer_bwfyhWa6rFaO8WGfxnN2PvV0BTsVTDvSo40Rw6pGSZlPV1TZTu152c0lKoeiKGVeRIzWI8ylmApYjdRpTU999mo98-2hDs1&t=638611161180000000" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ function WebForm_OnSubmit() { if (typeof(ValidatorOnSubmit) == "function" && ValidatorOnSubmit() == false) return false; return true; } //]]> </script> <div class="aspNetHidden"> <input type="hidden" name="__VIEWSTATEGENERATOR" id="__VIEWSTATEGENERATOR" value="2173C2F0" /> <input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="/wEdAAM3qFzftlC/ozt2Koh2adZmsK8Qcg6x7YEKBpnNUn26Cy8zACrOsmKsedR3ZCAsXqPJ/EelHeJrx7NtqXZ2CajjwXPsMHVZwbMuoqN74XDtRQ==" /> </div> <header> <div style="background-color:#000;"> <div class="content-wrapper"> <div style="color:#fff;padding-bottom:22px;"> <span style="float:right;"> <ul class="lang"> <li style="font-size:12px;color:#ABA9A9;"> <a href="/english/"> ENGLISH</a> </li> <li style="font-size:12px;color:#ABA9A9;">|</li> <li style="font-size:12px;color:#ABA9A9;"><a href="/japanese/"> JAPANESE</a></li> <li style="font-size:12px;color:#ABA9A9;"> | </li> <li style="font-size:12px;color:#fff;"> CONNECT WITH US:</li> <li class="nolink"> <a href="https://www.facebook.com/jcnnewswire" target="_blank" class="social"> <i class="fa fa-facebook-square"></i></a> </li> <li class="nolink"> <a href="https://twitter.com/JCNNewswire" target="_blank" class="social"><i class="fa fa-twitter-square"></i></a> </li> <li class="nolink"> <a href="/rssfeed/" class="social"><i class="fa fa-rss-square"></i></a> </li> </ul> </span> </div> </div> </div> <br /> <div class="content-wrapper"> <div class="feature-float-left"> <p class="site-title"><a href="../../../"> <img src="/Images/JCN-Newswire.jpg" width="300px"/></a></p> </div> <div class="float-right"> <nav class="topnav"> <ul class="nav nav-tabs"> <li role="presentation"><a href="../../../">Home</a></li> <li role="presentation"><a href="../../../About/">About</a></li> <li role="presentation"><a href="../../../Contact/">Contact</a></li> <li role="presentation"><a href="../../../Client/" id="A1">Log in</a></li> <li style="padding-top:5px;"> <span id="RequiredFieldSearch" style="color:Red;visibility:hidden;">*</span> <input name="ctl00$searchstring" type="text" id="searchstring" placeholder="Search for..." style="width:150px;height:30px;font-size:14px;" /><input type="submit" name="ctl00$SearchButton" value="Go!" onclick="javascript:WebForm_DoPostBackWithOptions(new WebForm_PostBackOptions("ctl00$SearchButton", "", true, "", "", false, false))" id="SearchButton" class="btn btn-default" type="submit" style="height:30px;font-size: 13px;margin-left:2px;background-color:#f2f2f2;border-color:#ccc;" /> </li> </ul> </nav> </div> </div> </header> <div id="body"> <section class="content-wrapper main-content clear-fix"> <!-- Go to www.addthis.com/dashboard to customize your tools --> <script type="text/javascript" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-54f7fe387839d451" async="async"></script> <ol class="breadcrumb"> <li><a href="/">Home</a></li> <li class="active">Press release</li> </ol> <table> <!-- Body --> <tr valign="top"><td> <div class="col-lg-12 clearfix"> <table width="100%"> <tr> <td> <div id="MainContent_CompanyInfo"> <span id="MainContent_releaseDate" class="small">Nov 20, 2024 10:24 JST</span><br /> <span id="MainContent_companyLogo"><img src="http://www.jcnnewswire.com/image/company/eisai.240.jpg" class="companyLogo"></span><br /> <span id="MainContent_companySource" class="small">Source: <a href="http://www.eisai.com" target="_blank">Eisai</a></span> </div> </td> <td class="float-right"> <div class="addthis_sharing_toolbox"></div> </td> </tr> </table> </div> <p style="padding-bottom:100px;"></p> <div class="col-lg-9"> <table> <tr><td> <div align="justify" class="title"><span id="MainContent_HeadLine" class="header">Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements</span></div> <div align="justify"><strong></strong></div> <div align="justify"><span id="MainContent_Body" class="bodytext"><p><strong>TOKYO, Nov 20, 2024 - (JCN Newswire) - </strong>Eisai Co., Ltd. announced today that it has launched fibroblast growth factor receptor (FGFR) selective tyrosine kinase inhibitor “TASFYGO® Tablets 35mg” (generic name: tasurgratinib succinate) in Japan for the treatment of patients with unresectable biliary tract cancer with FGFR2 gene fusions or rearrangements that progressed after cancer chemotherapy. The product received manufacturing and marketing approval in Japan on September 24, 2024, and was published in Japan’s National Health Insurance Drug Price List today.<br><br><img style="display: block; margin-left: auto; margin-right: auto;" src="https://photos.acnnewswire.com/TASFYGO.jpg" alt="" width="380" height="214"></p> <p>Discovered in-house by Eisai’s Tsukuba Research Laboratories, TASFYGO is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against FGFR1, FGFR2 and FGFR3.</p> <p>The approval of TASFYGO in Japan is based on data such as the results of a multicenter, open-label, single- arm clinical phase II trial (Study 201) conducted by Eisai in Japan and China.1 A companion diagnostic test to detect FGFR2 gene fusions or rearrangements for the use of TASFYGO in biliary tract cancer, “AmoyDx® FGFR2 Break-apart FISH Probe Kit” by Nihon Stery, Inc. (Headquarters: Tokyo) was approved in August 2024.(2)</p> <p>The estimated number of patients in Japan with biliary tract cancer is approximately 22,000,(3),(4) with approximately 25% of the five-year relative survival rate,(3) making it an intractable cancer with the second worst prognosis following pancreatic cancer. Since drug therapy options are limited in comparison with other cancers, it is a disease with significant unmet medical needs. FGFR2 gene fusions or rearrangements are observed in approximately 5-14% of intrahepatic cholangiocarcinoma, which accounts for 15-30% of biliary tract cancers.(5),(6),(7) FGFR genetic aberrations such as the gene fusions are known to be deeply involved in the proliferation, survival and migration of cancer cells as well as tumor angiogenesis and drug resistance. As these genetic aberrations in FGFRs have been observed in various other types of cancers as well as biliary tract cancer, there is growing interest in FGFRs as a promising target for cancer therapy.</p> <p>TASFYGO is produced at the Kawashima Industrial Park (Gifu Prefecture), using innovative Continuous Manufacturing and Real Time Release Testing, a manufacturing technology that ensures product quality within production processes. Continuous Manufacturing is a production method in which processing is carried out continuously from raw material input to formulation. By incorporating real-time quality monitoring technology, multiple manufacturing processes are integrated, enabling automatic production. This method allows for higher quality control compared to conventional processes that focus on product release testing, by utilizing data within the manufacturing process and reducing human-error through automation.</p> <p>Eisai aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals, by delivering TASFYGO as a new treatment option for biliary tract cancer with FGFR2 gene fusions or rearrangements.</p> <p><strong>Product Information</strong></p> <p>Brand name: TASFYGO® Tablets 35mg Generic name: Tasurgratinib succinate</p> <p>Indications: Unresectable biliary tract cancer with FGFR2 gene fusions or rearrangements that progressed after cancer chemotherapy</p> <p>Dosage and Administration: The usual adult dose of tasurgratinib is 140mg orally once daily under fasting conditions. The dose may be reduced appropriately according to the condition of the patient.</p> <p>National Health Insurance (NHI) Drug Price: TASFYGO Tablets 35 mg: ¥ 15,378.70 (per 1 tablet) Packaging: TASFYGO Tablets 35 mg: 56 tablets (14 tablet PTP sheet X 4)</p> <p><strong>About “TASFYGO® Tablets 35mg” (tasurgratinib succinate, Development Code: E7090)</strong></p> <p>Discovered in-house by Eisai’s Tsukuba Research Laboratories, TASFYGO is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against fibroblast growth factor receptors (FGFR) FGFR1, FGFR2 and FGFR3. Distinct from prior known FGFR inhibitors, TASFYGO has a basic structure which lacks the dimethoxyphenyl moiety, and in a kinetic interaction analysis study, it was observed that TASFYGO demonstrates antitumor activities due to inhibition of kinase activity with a binding mode (Type V) that exhibits rapid and potent binding as well as high selectivity to FGFR.(8),(9)</p> <p>In non-clinical studies for biliary tract cancer, NIH/3T3 cells expressing FGFR2-AHCYL1, FGFR2-KCTD1, FGFR2-BICC1 or FGFR2-TXLNA as FGFR2-fusion genes, provided by the National Cancer Center Japan, were used. The antitumor activity of TASFYGO against FGFR2 gene fusion-positive cancers was confirmed in these models by evaluating its effect on anchorage-independent growth and subcutaneously transplanted tumor growth in mice.(9)</p> <p>A Phase I clinical trial is underway in Japan in patients with estrogen receptor-positive and HER2-negative breast cancer.</p> <p><strong>About Real Time Release Testing</strong></p> <p>Real Time Release Testing is a quality control approach that ensures the quality of final products based on data from within the manufacturing process. Applying Real Time Release Testing requires a quality design approach based on Quality by Design (QbD), an advanced development method for manufacturing processes. QbD is a development method that emphasizes process control based on profound understanding of manufacturing processes, rather than conventional quality assurance methods which mainly focus on product release testing.</p> <p>Eisai integrates Process Analytical Technology (PAT) into QbD to achieve a higher level of quality control by managing critical attributes of pharmaceuticals within the production process.</p> <p>(1) Furuse J. et al. Pivotal single-arm, phase 2 trial of tasurgratinib for patients with fibroblast growth factor receptor (FGFR)-2 gene fusion-positive cholangiocarcinoma (CCA). 2024 ASCO Gastrointestinal Cancers Symposium; Abstract No. 471. <a href="https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.3_suppl.471">https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.3_suppl.471</a><br>(2) AmoyDx® FGFR2 Break-apart FISH Probe Kit Approved as Companion Diagnostic for Eisai’s Tasurgratinib in Japan. Available at: https://www.amoydiagnostics.com/about/press-releases/245 Last accessed: September 2024.<br>(3) Latest statistics, Cancer Information Service, National Cancer Center, Japan. (Japanese only)<br>(4) The 23rd Follow-up Survey Reports for Primary Liver Cancer Cases in Japan (2014-2015), 2023. (Japanese only)<br>(5) Arai Y. et al., Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma, Hepatology, 2014, 59, 1427-1434.<br>(6) Maruki Y. et al., Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study), J Gastroenterol. 2021; 56(3), 250-260.<br>(7) Tsujie M. et al., Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma, Jpn J Clin Oncol. 2021; 51(6): 911-917.<br>(8) Miyano SW. et al., E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models, Molecular Cancer Therapeutics, 2016, 15, 2630-2639.<br>(9) Kawano S. et al., Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion, Anticancer Research, 2024, 44, 2393-2406.</p> <p>Media Inquiries:<br>Public Relations Department, Eisai Co., Ltd.<br>+81-(0)3-3817-5120</p></span></div> <div align="justify"><span id="MainContent_CompanyName" class="bodytext"></span></div> <div align="justify"><span id="MainContent_CompanyBoiler" class="bodytext"></span></div> <div align="justify"><span id="MainContent_Contact" class="bodytext"></span></div> <div align="justify"><span id="MainContent_Source" class="note">Source: Eisai<BR />Sectors: Healthcare & Pharm <BR /><BR /></span></div> <div align="justify"><span id="MainContent_Copyright" class="bodytext"><p>Copyright 漏2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.<p></span></div> </td></tr> </table> <hr /> <h3><span id="MainContent_Label1">Latest Release</span></h3> <span id="MainContent_LatestRelease_LatestPressRelease"><table width="100%" cellpadding=0 cellspacing=0><tr><td class="articleDate"><img title="CleverTap" src="http://www.jcnnewswire.com/image/toppage/Clevertap64.jpg"><br /><a href="/pressrelease/94036/3/CleverTap-Recognized-as-a-Strong-Performer-in-the-Cross-Channel-Marketing-Hubs,-Q4-2024-Report" class="newslink">CleverTap Recognized as a 'Strong Performer' in the Cross-Channel Marketing Hubs, Q4 2024 Report</a><br /><span class="note"> Nov 23, 2024 21:42 JST</span><br /></td></tr><tr><td class="articleDate"><br /><a href="/pressrelease/94045/3/Kaplan-Fox-&-Kilsheimer-LLP-Alerts-Investors-to-a-Securities-Class-Action-Against-Humacyte,-Inc-(HUM" class="newslink">Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025</a><br /><span class="note"> Nov 22, 2024 11:00 JST</span><br /></td></tr><tr><td class="articleDate"><img title="NaaS Technology Inc." src="http://www.jcnnewswire.com/image/toppage/NAAS64.jpg"><br /><a href="/pressrelease/94025/3/NaaS-Q3-2024-Recap:-Strategic-Shifts-and-Tech-Innovations-for-Growth" class="newslink">NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth</a><br /><span class="note"> Nov 21, 2024 22:59 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Honda Motor Co, Ltd" src="http://www.jcnnewswire.com/image/toppage/honda.gif"><br /><a href="/pressrelease/94013/3/Honda-Unveils-Demonstration-Production-Line-for-All-Solid-State-Batteries-Located-in-Sakura-City,-To" class="newslink">Honda Unveils Demonstration Production Line for All-Solid-State Batteries Located in Sakura City, Tochigi Prefecture, Japan</a><br /><span class="note"> Nov 21, 2024 15:35 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Kaplan Fox & Kilsheimer LLP" src="http://www.jcnnewswire.com/image/toppage/Kaplan-Fox-Logo-Small.jpg"><br /><a href="/pressrelease/94009/3/Deadline-to-Lead-in-Securities-Fraud-Lawsuit-Against-Humacyte,-Inc-(HUMA)-is-January-17,-2025---Cont" class="newslink">Deadline to Lead in Securities Fraud Lawsuit Against Humacyte, Inc. (HUMA) is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP</a><br /><span class="note"> Nov 21, 2024 09:00 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Lexaria Bioscience" src="http://www.jcnnewswire.com/image/toppage/Lexaria.55.jpg"><br /><a href="/pressrelease/93991/3/ALL-Study-Groups-Using-DehydraTECH-Processing-Outperform-Rybelsus(R)-in-Body-Weight-Control-in-Lexar" class="newslink">ALL Study Groups Using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study</a><br /><span class="note"> Nov 20, 2024 23:05 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Mitsubishi Heavy Industries, Ltd." src="http://www.jcnnewswire.com/image/toppage/MHI_newT.jpg"><br /><a href="/pressrelease/93993/3/Start-of-Demonstration-Test-of-Two-Phase-Direct-to-Chip-Cooling-in-the-Air-Cooled-Data-Center" class="newslink">Start of Demonstration Test of Two-Phase Direct-to-Chip Cooling in the Air-Cooled Data Center</a><br /><span class="note"> Nov 20, 2024 15:30 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Eisai" src="http://www.jcnnewswire.com/image/toppage/eisai45.jpg"><br /><a href="/pressrelease/93992/3/Rozebalamin-for-Injection-25mg-(Mecobalamin)-for-Amyotrophic-Lateral-Sclerosis-Launched-in-Japan" class="newslink">Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan</a><br /><span class="note"> Nov 20, 2024 11:51 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Eisai" src="http://www.jcnnewswire.com/image/toppage/eisai45.jpg"><br /><a href="/pressrelease/93990/3/Anticancer-Agent-TASFYGO-Tablets-35mg-(Tasurgratinib-Succinate)-Launches-in-Japan-for-Biliary-Tract-" class="newslink">Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements</a><br /><span class="note"> Nov 20, 2024 10:24 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Kingsoft Corporation Limited" src="http://www.jcnnewswire.com/image/toppage/kingsoft.gif"><br /><a href="/pressrelease/93971/3/Kingsoft-Announces-2024-Third-Quarter-Results" class="newslink">Kingsoft Announces 2024 Third Quarter Results</a><br /><span class="note"> Nov 19, 2024 18:54 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Olympus" src="http://www.jcnnewswire.com/image/toppage/olympus-68.jpg"><br /><a href="/pressrelease/93934/3/NTT-and-Olympus-Joint-Demonstration-Shows-IOWN-APNs-Low-latency-Capability-Can-Be-Used-for-Real-time" class="newslink">NTT and Olympus Joint Demonstration Shows IOWN APN's Low-latency Capability Can Be Used for Real-time Diagnosis and Treatment on a Remote Server to Realize World's First Cloud Endoscopy System</a><br /><span class="note"> Nov 19, 2024 15:30 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Fujitsu Ltd" src="http://www.jcnnewswire.com/image/toppage/Fujitsu.Logo.68.jpg"><br /><a href="/pressrelease/93955/3/Supercomputer-Fugaku-retains-first-place-worldwide-in-HPCG-and-Graph500-rankings" class="newslink">Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings</a><br /><span class="note"> Nov 19, 2024 09:02 JST</span><br /></td></tr><tr><td class="articleDate"><img title="CleverTap" src="http://www.jcnnewswire.com/image/toppage/Clevertap64.jpg"><br /><a href="/pressrelease/93942/3/CleverTap-Recognized-as-a-Strong-Performer-in-Cross-Channel-Marketing-Hubs,-Q4-2024-Report" class="newslink">CleverTap Recognized as a Strong Performer in Cross-Channel Marketing Hubs, Q4 2024 Report</a><br /><span class="note"> Nov 18, 2024 23:30 JST</span><br /></td></tr><tr><td class="articleDate"><img title="NEC Corporation" src="http://www.jcnnewswire.com/image/toppage/NEC.62.jpg"><br /><a href="/pressrelease/93943/3/Worlds-First-Successful-Trial-of-Quantum-Tokens-Created-Using-Quantum-Technology" class="newslink">World's First Successful Trial of Quantum Tokens Created Using Quantum Technology</a><br /><span class="note"> Nov 18, 2024 17:29 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Fujitsu Ltd" src="http://www.jcnnewswire.com/image/toppage/Fujitsu.Logo.68.jpg"><br /><a href="/pressrelease/93935/3/Fujitsu-and-SAP-Fioneer-enter-partnership-to-accelerate-digital-transformation-in-the-insurance-indu" class="newslink">Fujitsu and SAP Fioneer enter partnership to accelerate digital transformation in the insurance industry and deliver services that contribute to customers' sustainable business</a><br /><span class="note"> Nov 18, 2024 12:31 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Toyota Motor Corporation" src="http://www.jcnnewswire.com/image/toppage/ToyotaBb.68.jpg"><br /><a href="/pressrelease/93931/3/Expanding-Possibilities-with-the-Liquid-Hydrogen-Powered-GR-Corolla-in-the-Season-Final-Round" class="newslink">Expanding Possibilities with the Liquid Hydrogen-Powered GR Corolla in the Season Final Round</a><br /><span class="note"> Nov 18, 2024 09:25 JST</span><br /></td></tr><tr><td class="articleDate"><br /><a href="/pressrelease/93927/3/COP29:-Indonesian-Special-Envoy-Hashim-Djojohadikusumo-Announces-EUR-1,2-Billion-Green-Funding" class="newslink">COP29: Indonesian Special Envoy Hashim Djojohadikusumo Announces EUR 1,2 Billion Green Funding</a><br /><span class="note"> Nov 16, 2024 18:00 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Mitsubishi Heavy Industries, Ltd." src="http://www.jcnnewswire.com/image/toppage/MHI_newT.jpg"><br /><a href="/pressrelease/93911/3/Mitsubishi-Shipbuilding-Holds-Christening-and-Launch-Ceremony-of-LNG-Powered-Roll-onRoll-off-Ship-TR" class="newslink">Mitsubishi Shipbuilding Holds Christening and Launch Ceremony of LNG-Powered Roll-on/Roll-off Ship TRANS HARMONY EMERALD in Shimonoseki</a><br /><span class="note"> Nov 15, 2024 18:58 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Eisai" src="http://www.jcnnewswire.com/image/toppage/eisai45.jpg"><br /><a href="/pressrelease/93908/3/Nationwide-TV-Commercial-Launched-in-Japan-to-Raise-Awareness-About-MCI-(Mild-Cognitive-Impairment)" class="newslink">Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)</a><br /><span class="note"> Nov 15, 2024 17:33 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Eisai" src="http://www.jcnnewswire.com/image/toppage/eisai45.jpg"><br /><a href="/pressrelease/93902/3/Eisai-Receives-Positive-Opinion-from-the-CHMP-in-the-European-Union-for-Lecanemab-in-Early-Alzheimer" class="newslink">Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease</a><br /><span class="note"> Nov 15, 2024 14:31 JST</span><br /></td></tr></table></span> <a id="MainContent_LatestRelease_MoreRelease" href="/MoreNews_j/3">More Latest Release >></a> </div> <div class="col-lg-3"> <span id="MainContent_RelatedNews_RelatedNews"><div class="sidebar-module-inset"><h4>Related Release</h4><table width="100%" cellpadding=0 cellspacing=0><tr><td><a href="/pressrelease/93992/3/Rozebalamin-for-Injection-25mg-(Mecobalamin)-for-Amyotrophic-Lateral-Sclerosis-Launched-in-Japan">Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan</a></td></tr><tr><td class="note">11/20/2024 11:51:00 AM JST</td></tr><tr><td> </td></tr><tr><td><a href="/pressrelease/93908/3/Nationwide-TV-Commercial-Launched-in-Japan-to-Raise-Awareness-About-MCI-(Mild-Cognitive-Impairment)">Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)</a></td></tr><tr><td class="note">11/15/2024 5:33:00 PM JST</td></tr><tr><td> </td></tr><tr><td><a href="/pressrelease/93902/3/Eisai-Receives-Positive-Opinion-from-the-CHMP-in-the-European-Union-for-Lecanemab-in-Early-Alzheimer">Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease</a></td></tr><tr><td class="note">11/15/2024 2:31:00 PM JST</td></tr><tr><td> </td></tr><tr><td><a href="/pressrelease/93674/3/Eisai&aposs-Corporate-Venture-Capital-Subsidiary,-Eisai-Innovation,-Inc,-Selected-for-AMED&aposs-&ap">Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"</a></td></tr><tr><td class="note">11/5/2024 11:35:00 AM JST</td></tr><tr><td> </td></tr><tr><td><a href="/pressrelease/93641/3/Eisai-Completes-Rolling-Submission-to-US-FDA-for-LEQEMBI(R)-(lecanemab-irmb)-Biologics-License-Appli">Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status</a></td></tr><tr><td class="note">11/1/2024 1:56:00 PM JST</td></tr><tr><td> </td></tr><tr><td><a href="/pressrelease/93626/3/Eisai-Presents-Data-on-Benefits-of-Long-Term-Administration-of-Dual-Acting-Lecanemab-at-the-17th-Cli">Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference</a></td></tr><tr><td class="note">10/31/2024 1:56:00 PM JST</td></tr><tr><td> </td></tr><tr><td><a href="/pressrelease/93621/3/Eisai-Presents-Latest-Clinical-Findings-Suggesting-Inhibition-of-Tau-Propagation-by-Anti-MTBR-Tau-An">Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)</a></td></tr><tr><td class="note">10/31/2024 11:33:00 AM JST</td></tr><tr><td> </td></tr><tr><td><a href="/pressrelease/93364/3/A-Joint-Regional-Cohort-Study-by-Shimadzu,-Eisai,-Oita-University,-and-Usuki-City-Medical-Associatio">A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association</a></td></tr><tr><td class="note">10/17/2024 8:01:00 PM JST</td></tr><tr><td> </td></tr><tr><td><a href="/pressrelease/93360/3/Update-on-Regulatory-Review-of-Lecanemab-for-Early-Alzheimer&aposs-Disease-in-Australia">Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia</a></td></tr><tr><td class="note">10/17/2024 3:59:00 PM JST</td></tr><tr><td> </td></tr><tr><td><a href="/pressrelease/93334/3/Amyotrophic-Lateral-Sclerosis-Treatment-"Rozebalamin(R)-for-Injection-25-mg"-Receives-The-Go">Amyotrophic Lateral Sclerosis Treatment "Rozebalamin(R) for Injection 25 mg" Receives The Good Design Award 2024 for Light- Proof Vial Packaging</a></td></tr><tr><td class="note">10/16/2024 7:14:00 PM JST</td></tr><tr><td> </td></tr><tr><td align="center"><a href="/CompanyNews/93990/3">More Press release >></a></td></tr></table></dl></div></span> </div> </td></tr> </table> <script type="text/javascript"> $(document).ready(function () { $("#single_1").fancybox({ helpers: { title: { type: 'float' } } }); }); </script> </section> </div> <footer> <div class="content-wrapper"> <div align="center"> Copyright © 2024 - JCN Newswire <div class="botton-nav"> <ul> <li><a href="../../../">Home</a></li> <li><a href="../../../About/">About</a></li> <li><a href="../../../Contact/">Contact</a></li> <li><a href="../../../RssFeed/">RSS</a></li> <li><a href="../../../Cookies/">Cookies Policy</a></li> <li><a href="../../../Disclaimer/">Disclaimer</a></li> <li><a href="../../../Privacy/">Privacy Policy</a></li> <li><a href="../../../Terms/">Terms of Use</a></li> <li> - </li> <li> Connect with us:</li> <li class="nolink"> <a href="https://www.facebook.com/jcnnewswire" target="_blank" class="social"> <i class="fa fa-facebook-square"></i></a> </li> <li class="nolink"> <a href="https://twitter.com/JCNNewswire" target="_blank" class="social"><i class="fa fa-twitter-square"></i></a> </li> <li class="nolink"> <a href="/rssfeed.aspx" class="social"><i class="fa fa-rss-square"></i></a> </li> </ul> </div> </div> </div> </footer> <script type="text/javascript"> //<![CDATA[ var Page_Validators = new Array(document.getElementById("RequiredFieldSearch")); //]]> </script> <script type="text/javascript"> //<![CDATA[ var RequiredFieldSearch = document.all ? document.all["RequiredFieldSearch"] : document.getElementById("RequiredFieldSearch"); RequiredFieldSearch.controltovalidate = "searchstring"; RequiredFieldSearch.errormessage = "*"; RequiredFieldSearch.evaluationfunction = "RequiredFieldValidatorEvaluateIsValid"; RequiredFieldSearch.initialvalue = ""; //]]> </script> <script type="text/javascript"> //<![CDATA[ var Page_ValidationActive = false; if (typeof(ValidatorOnLoad) == "function") { ValidatorOnLoad(); } function ValidatorOnSubmit() { if (Page_ValidationActive) { return ValidatorCommonOnSubmit(); } else { return true; } } //]]> </script> </form> <script> (function (i, s, o, g, r, a, m) i['GoogleAnalyticsObject'] = r; i[r] = i[r] || function () (i[r].q = i[r].q || []).push(arguments) }, i[r].l = 1 * new Date(); a = s.createElement(o), m = s.getElementsByTagName(o)[0]; a.async = 1; a.src = g; m.parentNode.insertBefore(a, m) })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga'); ga('create', 'UA-61831624-1', 'auto'); ga('send', 'pageview'); </script> </body> </html>